Comparison of the efficacy of third-line treatments for metastatic colorectal cancer: A network meta-analysis

被引：0
|
作者：
Taieb, J. [1 ]
Yahiaoui, S. [2 ]
Choucair, E. [3 ]
Yao, W. [4 ]
Hauch, O. [2 ]
机构：
[1] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France
[2] Lab Servier SAS, Global Value Access & Pricing Dept, Suresnes, France
[3] Lab Servier SAS, Med Affairs, Suresnes, France
[4] Servier Pharmaceut, Dept Clin Res, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
60P
引用
下载
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [41] A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
    Jing, Zhu
    Rui, Zhou
    Zhang binglan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (09) : 2313 - 2323
  • [42] A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
    Zhu Jing
    Zhou Rui
    Zhang binglan
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 2313 - 2323
  • [43] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [44] Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer
    Wu, Jing
    Chen, Wei-Kang
    Zhang, Wei
    Zhang, Jin-Song
    Liu, Jian-He
    Jiang, Yong-Ming
    Fang, Ke-Wei
    ONCOTARGET, 2017, 8 (35) : 59709 - 59719
  • [45] A Decade of Progress: Advances in the Third-Line Treatment of Patients With Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02): : S23 - S30
  • [46] Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.
    Li, Qiu
    Zhang, Mengxi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    CANCER SCIENCE, 2018, 109 : 601 - 601
  • [48] Refining the Use and Sequencing of Third-Line Therapy in Patients With Metastatic Colorectal Cancer
    Grothey, Axel
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 7 - 14
  • [49] Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer
    Xu, Shan
    Sak, Ali
    Erol, Yasin Bahadir
    CANCER CONTROL, 2021, 28
  • [50] Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
    Sadayuki Kawai
    Nozomi Takeshima
    Yu Hayasaka
    Akifumi Notsu
    Mutsumi Yamazaki
    Takanori Kawabata
    Kentaro Yamazaki
    Keita Mori
    Hirofumi Yasui
    BMC Cancer, 21
12345